TW202119030A - 以RGMa片段為主的診斷分析 - Google Patents

以RGMa片段為主的診斷分析 Download PDF

Info

Publication number
TW202119030A
TW202119030A TW109124697A TW109124697A TW202119030A TW 202119030 A TW202119030 A TW 202119030A TW 109124697 A TW109124697 A TW 109124697A TW 109124697 A TW109124697 A TW 109124697A TW 202119030 A TW202119030 A TW 202119030A
Authority
TW
Taiwan
Prior art keywords
rgma
kda
rgma fragment
content
fragment
Prior art date
Application number
TW109124697A
Other languages
English (en)
Chinese (zh)
Inventor
史戴芬 巴格霍恩
伯恩哈德 克勞斯 姆樂
馬汀 史克米迪
安德烈斯 史崔賓格
Original Assignee
德商艾伯維德國有限及兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商艾伯維德國有限及兩合公司 filed Critical 德商艾伯維德國有限及兩合公司
Publication of TW202119030A publication Critical patent/TW202119030A/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
TW109124697A 2014-09-10 2015-09-09 以RGMa片段為主的診斷分析 TW202119030A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
US62/048,745 2014-09-10

Publications (1)

Publication Number Publication Date
TW202119030A true TW202119030A (zh) 2021-05-16

Family

ID=54064367

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109124697A TW202119030A (zh) 2014-09-10 2015-09-09 以RGMa片段為主的診斷分析
TW104129821A TW201617612A (zh) 2014-09-10 2015-09-09 以ＲＧＭａ片段為主的診斷分析

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104129821A TW201617612A (zh) 2014-09-10 2015-09-09 以ＲＧＭａ片段為主的診斷分析

Country Status (10)

Country Link
US (3) US20160069907A1 (enExample)
EP (1) EP3191847A1 (enExample)
JP (1) JP6879905B2 (enExample)
CN (2) CN107076757A (enExample)
AU (2) AU2015314240A1 (enExample)
BR (1) BR112017004883A2 (enExample)
CA (1) CA2956814A1 (enExample)
MX (2) MX385216B (enExample)
TW (2) TW202119030A (enExample)
WO (1) WO2016038084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
CN116942831A (zh) 2018-07-19 2023-10-27 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
CN118767130A (zh) * 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
US12306192B2 (en) 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
EP4374300A4 (en) * 2021-07-23 2025-06-11 Cedars-Sinai Medical Center Methods and systems for the early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
KR102284780B1 (ko) * 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
EP3252072A3 (en) * 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas

Also Published As

Publication number Publication date
CN107076757A (zh) 2017-08-18
BR112017004883A2 (pt) 2017-12-05
AU2022200160A1 (en) 2022-02-10
US20160069907A1 (en) 2016-03-10
EP3191847A1 (en) 2017-07-19
US20220018855A1 (en) 2022-01-20
WO2016038084A1 (en) 2016-03-17
CA2956814A1 (en) 2016-03-17
US20200241012A1 (en) 2020-07-30
AU2015314240A1 (en) 2017-02-09
CN113267630A (zh) 2021-08-17
MX2021009528A (es) 2021-09-08
JP6879905B2 (ja) 2021-06-02
JP2017526930A (ja) 2017-09-14
MX385216B (es) 2025-03-14
MX2017003063A (es) 2017-06-14
TW201617612A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
US20220018855A1 (en) RGMa Fragment Based Diagnostic Assay
CN103959067B (zh) 用于检测和监测用于创伤后应激障碍（ptsd）的诊断生物标志物以及用于区分自杀式与非自杀式障碍的试剂盒
JP2004527754A (ja) アルツハイマー型痴呆の鑑別診断処理及びその装置
CN107636468A (zh) 用于预测认知退化的风险的方法
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
Minohara et al. Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity
WO2015034926A1 (en) Treatment methods for rheumatoid arthritis
Wang et al. Serum matrix metalloproteinase-2: A potential biomarker for diagnosis of epilepsy
Zheng et al. Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus
US7709215B2 (en) Method for diagnosing and treating acute joint injury
US20130183248A1 (en) Method and kit for detection of autoimmune chronic urticaria
US20030092089A1 (en) Method for diagnosing multiple sclerosis and an assay therefore
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
JP7713445B2 (ja) 薬物誘発細胞毒性及び鬱病のバイオマーカー
CN110988351A (zh) 血管细胞黏附分子在制备抑郁症诊断治疗相关产品的用途
US20120208718A1 (en) Schizophrenia treatment response biomarkers
WO2023143327A1 (zh) 缺氧诱导因子1α作为标志物在抑郁症复发诊断中的应用
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
US20210382049A1 (en) Assessing responsiveness of rheumatoid arthritis patients to biological treatment
EP3730942A1 (en) Diagnosis markers for atrial fibrillation
CN114137214B (zh) 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用
Akel Blood-based biomarkers in epilepsy
EP3570028A1 (en) Assessing responsiveness of rheumatoid arthritis patients to biological treatment
US20090162854A1 (en) Methods and kits for diagnosis of schizophrenia
WO2024223904A1 (en) Method and kit for establishing and monitoring treatments of chronic graft-versus-host disease (cgvhd) using cytokine or chemokines biomarkers